Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies

✍ Scribed by Patrizia Mecocci; Anna Bladström; Karina Stender

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 129 KB
• Volume: 24
• Category: Article
• ISSN: 0885-6230
• DOI: 10.1002/gps.2226

✦ Synopsis

Abstract

Objectives

The post‐hoc analyses reported here evaluate the specific effects of memantine treatment on ADAS‐cog single‐items or SIB subscales for patients with moderate to severe AD.

Methods

Data from six multicentre, randomised, placebo‐controlled, parallel‐group, double‐blind, 6‐month studies were used as the basis for these post‐hoc analyses. All patients with a Mini‐Mental State Examination (MMSE) score of less than 20 were included. Analyses of patients with moderate AD (MMSE: 10–19), evaluated with the Alzheimer's disease Assessment Scale (ADAS‐cog) and analyses of patients with moderate to severe AD (MMSE: 3–14), evaluated using the Severe Impairment Battery (SIB), were performed separately.

Results

The mean change from baseline showed a significant benefit of memantine treatment on both the ADAS‐cog (p < 0.01) and the SIB (p < 0.001) total score at study end. The ADAS‐cog single‐item analyses showed significant benefits of memantine treatment, compared to placebo, for mean change from baseline for commands (p < 0.001), ideational praxis (p < 0.05), orientation (p < 0.01), comprehension (p < 0.05), and remembering test instructions (p < 0.05) for observed cases (OC). The SIB subscale analyses showed significant benefits of memantine, compared to placebo, for mean change from baseline for language (p < 0.05), memory (p < 0.05), orientation (p < 0.01), praxis (p < 0.001), and visuospatial ability (p < 0.01) for OC.

Conclusion

Memantine shows significant benefits on overall cognitive abilities as well as on specific key cognitive domains for patients with moderate to severe AD. Copyright © 2009 John Wiley & Sons, Ltd.